Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab

J Allergy Clin Immunol Pract. 2017 Mar-Apr;5(2):498-501. doi: 10.1016/j.jaip.2016.11.010. Epub 2016 Dec 22.
No abstract available

Publication types

  • Case Reports
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Allergens / immunology
  • Arachis / immunology
  • Child
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Eosinophilic Esophagitis / diagnosis*
  • Eosinophilic Esophagitis / etiology
  • Female
  • Humans
  • Immunoglobulin E / blood
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Male
  • Omalizumab / adverse effects
  • Omalizumab / therapeutic use*
  • Peanut Hypersensitivity / drug therapy*
  • Young Adult

Substances

  • Allergens
  • Omalizumab
  • Immunoglobulin E